← 返回前沿论文

PD-1 和 ICOS 共表达可识别人类实体瘤中的肿瘤反应性 CD4+ T 细胞

英文原题:PD-1 and ICOS coexpression identifies tumor-reactive CD4+ T cells in human solid tumors.

PubMed 2022/06/15(内容时间) J Clin Invest Q1 · IF 14.3(JCR 2025)

研究概要

CD4+ Th细胞在协调免疫反应中发挥关键作用,但参与抗肿瘤免疫反应的CD4+ Th细胞的身份仍有待确定。

中文摘要

CD4+ Th细胞在协调免疫反应中发挥关键作用,但参与抗肿瘤免疫反应的CD4+ Th细胞的身份仍有待确定。我们分析了头颈部鳞状细胞癌和结直肠癌的免疫细胞浸润,并鉴定出一个不同于FOXP3+ Tregs的CD4+ Th细胞亚群,该亚群共表达programmed cell death 1(PD-1)和ICOS。这些TIL(肿瘤浸润淋巴细胞)CD4+ Th细胞(CD4+ Th TILs)具有组织驻留记忆表型,存在于MHC II类分子丰富的区域,并在肿瘤中增殖,提示存在局部抗原识别。PD-1+ICOS+ CD4+ Th TILs的T细胞受体库呈寡克隆性,T细胞克隆在肿瘤中扩增,但在外周中以低频率存在。最后,这些PD-1+ICOS+ CD4+ Th TILs被证明可识别肿瘤相关抗原和肿瘤特异性新抗原。我们的发现提供了一种直接离体分离肿瘤反应性CD4+ Th TILs的方法,这将有助于明确其在抗肿瘤免疫反应中的作用,并可能改善未来的过继性T细胞治疗方法。

展开英文摘要原文

CD4+ Th cells play a key role in orchestrating immune responses, but the identity of the CD4+ Th cells involved in the antitumor immune response remains to be defined. We analyzed the immune cell infiltrates of head and neck squamous cell carcinoma and colorectal cancers and identified a subset of CD4+ Th cells distinct from FOXP3+ Tregs that coexpressed programmed cell death 1 (PD-1) and ICOS. These tumor-infiltrating lymphocyte CD4+ Th cells (CD4+ Th TILs) had a tissue-resident memory phenotype, were present in MHC class II-rich areas, and proliferated in the tumor, suggesting local antigen recognition. The T cell receptor repertoire of the PD-1+ICOS+ CD4+ Th TILs was oligoclonal, with T cell clones expanded in the tumor, but present at low frequencies in the periphery. Finally, these PD-1+ICOS+ CD4+ Th TILs were shown to recognize both tumor-associated antigens and tumor-specific neoantigens. Our findings provide an approach for isolating tumor-reactive CD4+ Th TILs directly ex vivo that will help define their role in the antitumor immune response and potentially improve future adoptive T cell therapy approaches.

论文信息

作者
Duhen R、Fesneau O、Samson KA、Frye AK、Beymer M、Rajamanickam V、Ross D、Tran E
单位
Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA.Chile
文献类型
非美国政府资助研究
期刊
The Journal of clinical investigation2022 Jun 15
原文标识
PubMed 35439168 · DOI 10.1172/JCI156821